This article is
- freely available
Antibodies 2012, 1(1), 70-87; doi:10.3390/antib1010070
Department of Chemistry and Applied Biosciences, ETH Zürich, Wolfgang-Pauli-Strasse 10, CH-8093 Zürich, Switzerland
* Author to whom correspondence should be addressed.
Received: 27 April 2012; in revised form: 15 May 2012 / Accepted: 17 May 2012 / Published: 31 May 2012
(This article belongs to the Special Issue Modes of Antibody Action for Cancer Therapy)
Download PDF Full-Text [311 KB, uploaded 1 June 2012 07:54 CEST]
Abstract: A number of cytokines have shown beneficial effects in preclinical animal models of cancer and chronic inflammatory diseases. However, cytokine treatment is often associated with severe side effects, which prevent the administration of clinically relevant doses in humans. Immunocytokines are a novel class of biopharmaceuticals, consisting of a cytokine moiety fused to monoclonal antibodies or to an antibody fragment, which selectively accumulate at the disease site and thereby enhance the therapeutic effects of cytokines. This review surveys the recent preclinical and clinical advances in the field, with a special focus on the impact of antibody formats, target antigen and cytokine moieties on the therapeutic performance in vivo. We also discuss emerging data about the possibility to combine immunocytokines with other pharmacological agents.
Keywords: immunotherapy; immunocytokines; cytokines; antibodies; antibody formats; cancer; chronic inflammatory disease
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
MDPI and ACS Style
Gutbrodt, K.L.; Neri, D. Immunocytokines. Antibodies 2012, 1, 70-87.AMA Style
Gutbrodt KL, Neri D. Immunocytokines. Antibodies. 2012; 1(1):70-87.Chicago/Turabian Style
Gutbrodt, Katrin L.; Neri, Dario. 2012. "Immunocytokines." Antibodies 1, no. 1: 70-87.